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Abstract
Tuberculosis, caused by Mycobacterium tuberculosis infection, is a major cause of morbidity and mortality in the world today.
M. tuberculosis hijacks the phagosome-lysosome trafficking pathway to escape clearance from infected macrophages. There
is increasing evidence that manipulation of autophagy, a regulated catabolic trafficking pathway, can enhance killing of M.
tuberculosis. Therefore, pharmacological agents that induce autophagy could be important in combating tuberculosis. We
report that the antiprotozoal drug nitazoxanide and its active metabolite tizoxanide strongly stimulate autophagy and
inhibit signaling by mTORC1, a major negative regulator of autophagy. Analysis of 16 nitazoxanide analogues reveals similar
strict structural requirements for activity in autophagosome induction, EGFP-LC3 processing and mTORC1 inhibition.
Nitazoxanide can inhibit M. tuberculosis proliferation in vitro. Here we show that it inhibits M. tuberculosis proliferation more
potently in infected human THP-1 cells and peripheral monocytes. We identify the human quinone oxidoreductase NQO1 as
a nitazoxanide target and propose, based on experiments with cells expressing NQO1 or not, that NQO1 inhibition is partly
responsible for mTORC1 inhibition and enhanced autophagy. The dual action of nitazoxanide on both the bacterium and
the host cell response to infection may lead to improved tuberculosis treatment.
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Introduction
Mycobacterium tuberculosis (Mtb) is the bacterial pathogen that
causes tuberculosis, a major infectious disease responsible for
approximately 2 million deaths worldwide each year [1]. There is
a major need for more effective therapy against tuberculosis [2,3].
Mtb is a highly persistent and successful pathogen in part because
of its ability to manipulate intracellular membrane trafficking
events in host macrophages [4,5]. Upon entering the host cell, Mtb
resides in single-membraned phagosomes and initiates mecha-
nisms to avoid the innate immune response that can activate
macrophages [6–9]. A series of fusion events with various
endocytic organelles, culminating in fusion with lysosomes,
normally converts the phagosome into a phagolysosome that can
destroy its microbial contents [7]. Mtb prevents this conversion at
an early stage by secreting a protein phosphatase, PtpA, that
blocks the acquisition of the vacuolar-type H
+-ATPase required
for acidification of the lumen [10–13], limiting the acquisition of
lysosomal hydrolases and depleting the phagosome of phosphati-
dylinositol 3-phosphate [7,14,15].
Autophagy is another intracellular membrane trafficking
pathway that can play a role in controlling bacterial infection
[16,17]. In this process, cytoplasmic constituents are sequestered in
double-membraned structures called autophagosomes that are
subsequently targeted for fusion with lysosomes and are degraded
[18]. Under basal conditions this degradative pathway is
important for recycling intracellular material and organelles to
maintain cellular homeostasis. Experimental induction of autoph-
agy in macrophages by starvation, rapamycin, interferon-c or its
downstream effector LRG-47, toll-like receptor stimulation, ATP
stimulation, or by small molecules reduced survival of intracellular
Mtb [8,19–23]. This was associated with increased acidification of
phagosomes and increased colocalization of lysosomal and
autophagosomal markers with Mtb-containing phagosomes
[8,19,20], suggesting the block to phagosome maturation was
overcome and fusion with lysosomal and autophagosomal
compartments occurred. Further work has shown that the reduced
Mtb survival is associated with delivery to the Mtb compartment
of autophagosomal protein cargo that is proteolysed to generate
cationic peptides that are toxic to Mtb [24,25].
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rapamycin complex 1 (mTORC1), a nutrient-, energy- and
growth factor-sensing master regulator of cell growth and
metabolism [26]. mTORC1 is stimulated by growth factors and
nutrients to promote anabolic processes such as translation and
protein synthesis. Conversely, nutrient deprivation, cellular stress
and the chemical rapamycin inhibit mTORC1, leading to the
attenuation of anabolic reactions and the induction of autophagic
catabolism as a protective function [27].
The evidence supporting a protective, cell-clearing function for
autophagy in Mtb-infected macrophages suggests autophagy and
mTORC1 signaling as attractive targets for new treatments for
tuberculosis. Few studies have explored the use of approved drugs
to manipulate autophagy or mTORC1 to combat Mtb infection.
We recently reported results of a screen for chemicals that increase
autophagosome formation and identified niclosamide, an ap-
proved salicylanilide antihelmintic drug, as a potent stimulator of
autophagy and inhibitor of mTORC1 signaling [28]. Although
niclosamide is very effective in the intestinal tract, it is not a good
candidate for Mtb treatment because of its poor absorption. In the
present paper we examine whether nitazoxanide (NTZ, 2-
acetyloxy-N-(5-nitro-2-thiazolyl)benzamide, Alinia), a newer anti-
parasitic drug that was synthesized based on the structure of
niclosamide [29] and that shows good gastrointestinal absorption,
might also affect autophagy and mTORC1 activity and be a better
drug candidate for Mtb treatment.
We report that NTZ stimulates autophagy, inhibits mTORC1
signaling, and inhibits Mtb intracellular proliferation at concen-
trations found in the blood in humans after administration of a
standard oraldose. We show that NTZ inhibits the enzymatic
activity of human quinone oxidoreductase NQO1,probably acting
upstream of mTORC1 to stimulate autophagy. We also provide
insights into the structural requirements of NTZ for activity. Our
work further supports a mechanistic link between autophagy and
Mtb proliferation, and presents an additional option for the
manipulation of autophagy in the treatment of Mtb.
Results
Nitazoxanide modulates autophagy
NTZ (Figure 1A) structurally resembles niclosamide, a drug that
stimulates autophagy and inhibits signaling by mTORC1, a
negative regulator of autophagy [28]. NTZ is a prodrug that is
rapidly hydrolyzed in plasma to the active metabolite tizoxanide
(TIZ; Figure 1A) [30]. We therefore examined the effects of both
NTZ and TIZ on autophagy. The formation of autophagosomes
entails the recruitment of cytosolic Atg8/LC3 to nascent
autophagosomes [31]. This process can be monitored quantita-
tively by automated fluorescence microscopy in MCF-7 cells
expressing LC3 fused to EGFP (EGFP-LC3) as a shift from diffuse
to punctate cytoplasmic fluorescence [28]. Cells were exposed for
3 h or 24 h to concentrations of NTZ or TIZ ranging from 0.1 to
100 mM. Untreated cells showed mostly diffuse cytosolic EGFP-
LC3 staining and a low level of punctate EGFP-LC3, representing
basal levels of autophagy (Figure 1B, C). After 3 hincubation, NTZ
and TIZ caused a concentration-dependent increase in autopha-
gosomes that was detectable at 3 mM and maximal at 30 mM
(Figure 1B and Figure S1). After 24 h incubation, autophagosome
accumulation was even more pronounced (Figure 1B and Figure
S1).
Autophagosome accumulation observed in a static image may
reflect increased autophagic flux but has also been observed in the
presence of chemicals that decrease autophagic flux by inhibiting
the final stage of autophagy in which autophagosomes fuse with
lysosomes and are degraded [32]. To distinguish between these
possibilities, the effect of NTZ and TIZ on EGFP-LC3 processing
and degradation was examined by immunoblotting. Recruitment
of LC3 or EGFP-LC3 to autophagosomes involves its proteolytic
cleavage and lipidation, yielding a species with increased
electrophoretic mobility termed LC3II/EGFP-LC3II [31]. Upon
fusion with lysosomes, the contents of autophagosomes, including
sequestered LC3, are degraded by lysosomal hydrolases. However,
the free EGFP portion is degraded more slowly than LC3 itself,
leading to transient accumulation of a band corresponding to the
size of EGFP (,25 kD) [32].
Untreated cells showed mostly full length EGFP-LC3 and only a
small amount of free EGFP (Figure 2A). Incubation with NTZ or
TIZ for 4 h (Figure 2A) and 24 h (Figure 2B) caused a
concentration-dependent increase in the lipidated product
EGFP-LC3II that was visible at 3 mM and strong at $10 mM.
These results show the drugs increased the processing of EGFP-
LC3 that accompanies autophagosome formation. NTZ and TIZ
also caused an increase in the free EGFP band (Figure 2A, B) that
was abolished in the presence of the vacuolar-type H
+ ATPase
inhibitor bafilomycin A1 (Figure 2C), a known inhibitor of
lysosomal fusion [33,34]. This shows that NTZ and TIZ can
increase autophagic flux. Concentrations of NTZ and TIZ
$30 mM resulted in decreased free EGFP, despite the presence
of an EGFP-LC3II band (Figure 2A,B), raising the possibility that
autophagic flux was reduced at high concentrations of NTZ and
TIZ.As discussed further below, a decrease could be a conse-
quence of activation of PKB/Akt (Figure 2A, B), which is known
to downregulate autophagy [35,36].
Nitazoxanide inhibits mTORC1 but not mTORC2 signaling
mTORC1 is a protein kinase complex whose activity may be
monitored by measuring phosphorylation of key substrates such as
ribosomal S6 kinases (S6Ks) by immunoblotting [37]. Cells maintained
in complete cell culture medium containing serum and nutrients
showed high levels of Thr
389 phosphorylation by mTORC1 and
increased electrophoretic mobility of p70
S6Kandp85
S6K(Figure 2A) and
this was completely repressed within 4 h exposure to the mTORC1
inhibitor rapamycin (Figure 2A). Exposure to different concentrations
o fN T Zo rT I Zf o r4ho r2 4hr e s u l t e di nac o n c e n t r a t i o n - d e p e n d e n t
decrease inS6K phosphorylation - inhibition was partial at 1 mM,
strong at 3 mM and essentially complete at 10 mM(Figure 2A,B). Thus,
NTZ and TIZ inhibit mTORC1 signaling.
Author Summary
Tuberculosis is responsible for approximately 2 million
deaths worldwide each year. Current treatment regimens
require administration of multiple drugs over several
months and resistance to these drugs is on the rise.
Mycobacterium tuberculosis, the causative agent of the
disease, can proliferate within host cells. It has been
recently observed that autophagy (cellular self-eating) can
kill intracellular M. tuberculosis. We report that the
antiprotozoal drug nitazoxanide and its metabolite tizox-
anide induce autophagy, inhibit signaling by mTORC1, a
major negative regulator of autophagy, and prevent M.
tuberculosis proliferation in infected macrophages. We
show that nitazoxanide exerts at least some of its
pharmacological effects by targeting the quinone reduc-
tase NQO1. Our results uncover a novel mechanism of
action for the drug nitazoxanide, and show that pharma-
cological modulation of autophagy can suppress intracel-
lular M. tuberculosis proliferation.
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mTORC2 that phosphorylates PKB/Akt at Ser
473 [38]. The
rapamycin insensitive mTORC2 modulates changes in the
cytoskeleton and is largely unaffected by nutrients or energy
conditions [39]. To determine whether NTZ and TIZ inhibit
mTORC2, the same cell lysates were probed with a PKB/Akt
Ser
473 phosphospecific antibody. Untreated cells displayed
mTORC2 activity that was not inhibited by rapamycin(Figure 2A,
B). In fact, rapamycin caused an increase in mTORC2 activity
(Figure 2A, B). This is consistent with previous studies showing that
mTORC1/S6K1 signaling downregulates PKB/Akt phosphoryla-
tion on Ser
473 via a feedback loop involving transcriptional
inhibition of the insulin receptor substrate IRS-1 gene and
degradation of IRS-1 and IRS-2 proteins, and that mTORC1
inhibition prevents the establishment of this feedback loop, thus
increasing PKB/AktSer
473phosphorylation[40,41]. NTZand TIZ
also did not decrease PKB/Akt Ser
473 phosphorylation but rather
increased it in a concentration-dependent manner that paralleled
their level of mTORC1 inhibition (Figure 2A, B).The increase in
PKB/AKT Ser
473 phosphorylation at higher concentrations of
NTZ and TIZ was concomitant with the decrease in free EGFP
(Figure 2A, B). Since PKB/Akt downregulates autophagy [42], it is
possible that at high concentrations of NTZ and TIZ and long
incubation times, inhibition of mTORC1 stimulates autophagy
while feedback activation of PKB/Akt elicits signals that counteract
autophagy.
Inhibition of mTORC1 signaling was detectable after 30 min
exposure to 10 mM NTZ or TIZ and maximal after $1h
(Figure 3A) and PKB/Akt Ser
473 phosphorylation rose detectably
at 30 min and increased further at longer exposure times
(Figure 3A). To examine whether mTORC1 signaling inhibition
was reversible, cells were incubated with 10 mM NTZ or TIZ for
4 h, the drugs were washed away and the cells were incubated in
drug-free medium for different times. As a comparison, cells were
treated with rapamycin, which inhibits mTORC1 essentially
irreversibly. mTORC1 was strongly inhibited after 4 h exposure
to either NTZ or TIZ (Figure 3B, 0 h) but its activity increased
over time after drug removal, returning to levels seen in untreated
cells within 4 h, while mTORC1 activity remained profoundly
inhibited upon rapamycin withdrawal (Figure 3B).
Together, these results show that NTZ and TIZ strongly but
reversibly inhibit mTORC1 signaling. Since the mTOR catalytic
subunit is shared by mTORC1 and mTORC2, the observation
that the drugs inhibit mTORC1 while activating mTORC2 is
strong evidence that they do not directly inhibit the kinase activity
of mTOR itself but likely act on an upstream mTORC1
regulatory pathway.
Structural requirements for stimulation of autophagy and
inhibition of mTORC1 by nitazoxanide
NTZ targets in mammals are not well-characterized. To address
its mechanism of action in human cells, we first carried out a
limited structure-activity relationship study. Sixteen analogues
(Figure 4 and Figure S2) were synthesized and tested for effects on
autophagosome accumulation, EGFP-LC3 processing and inhibi-
tion of mTORC1 activity (Table 1).
NTZ and TIZ(Figure 4) showed similarly strong activity in all
three assays (Table 1). Analogue 1 lacking the OH group was
completely inactive in all three assays, implying that generation of
the OH group by hydrolysis of NTZ is essential for activity. In
support of this point, analogue 2 with an ether bond that is not
cleavable by esterases was inactive in all three assays (Table 1). In
addition, analogue 3 bearing a methylacetate substituent like NTZ
but arranged such that cleavage by esterases would generate a
carboxylic acid instead of an OH, was also inactive in all assays.
Moreover, analogues 4, 5 and 6, bearing more bulky propionate,
isobutyrate and pivalate substituents that are cleaved more slowly
by esterases, were also active in all three assays. Together, these
data show that NTZ is the active prodrug of TIZ and that the OH
group is critical for activity.
Methylation of the NH group in the linker region (compound 7,
Figure 4) caused complete loss of activity, suggesting that inter- or
intramolecular hydrogen bonding by the secondary amine or the
generation of an anionic form of NTZ [43] is required for activity.
Nitazoxanide also possesses a conspicuous nitro group attached to
the 5-membered ring (Figure 4). Analogue 8 lacking this group was
completely inactive in all three assays, showing the nitro group is
also required for activity. Analogue 9 with an aldehyde substituent
was also inactive, indicating that the strongly electron-withdrawing
character of the nitro group is more relevant to activity than its
steric bulk.
Addition of one or two chlorine substituents to the 6-membered
ring of NTZ also eliminated activity. Since niclosamide possesses a
Cl substituent para to the OH group, this result indicates that
NTZ and niclosamide probably have different cellular targets.
Several combinations of substitutions described individually above
were also inactive in all assays(Table 1, Figure S1).
Together, these results show that the OH, NH and NO2 groups
are all essential for induction of autophagosome accumulation,
EGFP-LC3 processing and mTORC1 inhibition, revealing strict
structural requirements for activity. The tight correlation between
the structural features required for activity in all three assays also
strongly implies that these biological responses are linked and
probably result from inhibition of a single target rather than
multiple independent targets.
Nitazoxanide and tizoxanide inhibit intracellular Mtb
proliferation
We next used a luciferase reporter assay to assess the ability of
NTZ to inhibit Mtb growth in infected macrophages. Differen-
tiated THP-1 human acute monocytic leukemia cells were infected
with a Mtb strain expressing luciferase. After removal of non-
internalized bacteria, NTZ was added and Mtb proliferation was
determined 24, 48, and 72 h later. NTZ showed concentration-
dependent inhibition at all time points, with essentially complete
inhibition at 10 mM (Figure 5A). Exposure of Mtb in liquid culture
to 10 mM NTZ was able to reduce Mtb growth, albeit less potently
compared to the growth in THP-1 cells (Figure S3).
To examine the reversibility of the effects of NTZ, infected
THP-1 cells were treated with NTZ for 24 h after which time the
drug was removed and cells were cultured for up to two additional
days. Exposure to 3 mMo r1 0mM NTZ significantly reduced Mtb
proliferation at 24 h but intracellular Mtb proliferation resumed
upon drug removal (Figure 5B). Immunoblotting for endogenous
LC3 and for phospho-Thr
389S6K indicated that autophagy was
induced by NTZ and TIZ in THP-1 cells, and that mTORC1 was
inhibited (Figure 5C). Rapamycin, which does not inhibit all
functions of mTORC1 and is a weak stimulator of autophagy
Figure 1. Induction of autophagosomes by NTZ and TIZ. (A)Structures of NTZ and TIZ. (B) Punctate EGFP-LC3 levels in MCF-7 cells stably
expressing EGFP-LC3. Accumulation was measured quantitatively by automated microscopy in cells incubated for 3 h or 24 h with different
concentrations of NTZ or TIZ. (C) Representative images of cells showing EGFP-LC3 (green) and DNA (blue).Scale bar, 10 mm.
doi:10.1371/journal.ppat.1002691.g001
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(Figure 5A, B, and Figure S4) or in liquid culture in the absence of
cells (Figure S3),had only a modest effect on the conversion of LC3
to LC3II, while completely inhibiting Thr
389S6K phosphorylation
(Figure 5C), and did not affect THP-1 cell survival (Figure 5D–F).
We also assessed the effect of NTZ on the viability of
differentiated THP-1 cells using three different assays: the MTT
assay to measure cell metabolic activity (Figure 5D), propidium
iodide (PI) exclusion to measure plasma membrane integrity
(Figure 5E),and staining of live cells with Hoechst 33342 to count
attached cells. The MTT assay showed a modest time- and
concentration-dependent reduction in THP-1 cell metabolic
activity (Figure 5D), as did the Hoechst 33342 assay (unpublished
data). By contrast, after 72 h of treatment with 10 mM NTZ, large
numbers of cells had taken up PI (Figure 5E).Cells treated with
NTZ for 24 h and transferred to drug-free medium retained
viability (Figure 5F).
The observation that after 72 h 10 mM NTZ had only minor
effects in the MTT assay but strongly increased PI uptake in
differentiated THP-1 cells was perplexing. Cellular toxicity was
unexpected given the knowledge that peak plasma concentrations
of approximately 37 mM are achieved after a standard oral dose of
500 mg NTZ [30] and that NTZ has an excellent safety profile,
with no significant side effects in patients taking 500 mg NTZ
twice daily for 24 weeks [46]. We therefore considered it
important to examine the effects of NTZ on human primary
peripheral blood mononuclear cells (PBMC), as cells of more
direct relevance to Mtb therapy.
PBMC were isolated from blood samples from a number of
healthy human donors. Cells were infected with Mtb at a
multiplicity of infection (MOI) of 1 or 10 for 24 h, after which
non-internalized bacteria were washed away and infected cells
were exposed to 3–30 mM NTZ for up to 72 h. The effect of
10 mM NTZ on intracellular Mtb proliferation ranged from 0 to
55% inhibition at 72 h, depending on the donor and the
multiplicity of infection (Figure 6A–C). 30 mM NTZ almost
completely inhibited Mtb proliferation, starting as early as 24 h
(Figure 6B, C).Notably, exposure of PBMC to NTZ at 10 mMo r
30 mM for up to 72 h caused no cytotoxicity, with cell survival
remaining at 100%, in both the PI uptake and MTT assays
(Figure 6D–F). By contrast, rapamycin reduced cell survival to
,30% (Figure 6D–E).
These observations show that NTZ can inhibit the intracellular
proliferation of Mtb at concentrations that are not toxic to primary
human cells. They are consistent with previous observations that
rapamycin has toxic effects on primary human cells [47]and that
NTZ is safe in humans at a plasma concentration of 30 mM
[30,48].
Nitazoxanide inhibits the human NAD(P)H quinone
oxidoreductase NQO1
Nitazoxanide has no known targets in humans. Our results thus
far suggest that it may target an upstream mTORC1 regulatory
pathway rather than acting directly on mTORC1 or autophagy. It
has recently been observed using affinity chromatography that
RM4847, a bromo derivative of TIZ, can bind human quinone
oxidoreductase NQO1 [49]. We used a modified version of the
Prochaska microtiter assay to monitor the effects of NTZ on
NQO1 activity [50,51]. NTZ was able to inhibit purified NQO1 in
vitro in a concentration-dependent manner, as did dicoumarol
(DIC), a known competitive inhibitor of NQO1 enzymatic activity
[52] (Figure 7A). Rapamycin, at a concentration that completely
inhibits mTORC1(0.1 mM),did not cause significant NQO1
inhibition, and NQO1 remained 60% active at a very high
Figure 2. Increased EGFP-LC3 processing and inhibition of
mTORC1 signaling by NTZ and TIZ. Cells were treated with the
indicated concentrations of NTZ, TIZ or rapamycin for 4 h (A) or 24 h (B).
In panel C, cells were treated with 10 mM NTZ, 10 mM TIZ, 30 nM
rapamycin, or DMSO without or with 0.1 mM bafilomycin A1 for 4 h.
EGFP-LC3 processing was examined by immunoblotting with antibodies
against GFP, mTORC1 activity using antisera against phospho-S6K Thr
389
and total S6K, and mTORC2 activity with antisera against phospho-AKT
Ser
473 and total AKT. Total AKT was also used as a loading control.
doi:10.1371/journal.ppat.1002691.g002
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performed the Prochaska assay on freshly prepared MCF-7 cell
lysates. Cellular NQO1 activity was reduced to approximately
14% by 10 mM NTZ (Figure 7B), a concentration that inhibits
mTORC1 in cells.
We also observed that the NQO1 inhibitor DIC can strongly
inhibit mTORC1, as assessed by S6K phosphorylation at 4 h
(Figure 7C), raising the possibility that NQO1 may be an upstream
regulator of mTORC1. The TSC1–TSC2 tuberous sclerosis
complex is a major negative upstream regulator of mTORC1 and
mouse embryo fibroblasts (MEFs) lacking the TSC2 gene
(TSC2
2/2) show high mTORC1 activity compared to TSC2
+/
+MEFs [53]. NTZ and DIC inhibited mTORC1 in TSC2
+/+ cells
but not in TSC2
2/2 cells (Figure 7D), indicating that inhibition is
dependent on the TSC1–TSC2 complex. We also examined the
effects of NTZ on HEK 293T cells, which do not express NQO1
at a detectable level (Figure 7E). Concentrations of NTZ or DIC
that significantly inhibited mTORC1 in MCF-7 cells, which
express a much higher level of NQO1 protein (Figure 7E),did not
exert as great an effect on mTORC1 signaling in HEK 293T cells
(Figure 7F). These data are consistent with inhibition of NQO1
leading to downstream mTORC1 inactivation by a pathway
involving the TSC1–TSC2 complex. By contrast, rapamycin
inhibited mTORC1 equally in both cell lines (Figure 7D–F). The
different cellular targets of rapamycin and NTZ may explain why
rapamycin was unable to inhibit intracellular Mtb proliferation in
infected cells.
Tuberculosis drugs do not interfere with the ability of
NTZ and TIZ to induce autophagosome formation
Tuberculosis is always treated with drug combinations. We
therefore asked whether NTZ and TIZ retain their ability to
induce autophagosomes in the presence of tuberculosis drugs.
MCF-7 cells were exposed to ethambutol (EMB), isoniazid (INH),
Figure 3. Time-course and reversibility of mTORC1 inhibition and EGFP-LC3 processing by NTZ and TIZ. (A) Cells were incubated with
10 mM NTZ or 10 mM TIZ for the indicated times. (B) Cells were incubated with 10 mM NTZ, 10 mM TIZ or 30 nM rapamycin for 4 h. The drugs were
then washed away and cells were incubated in drug-free medium for the indicated times post-washout. Cell lystates were immunoblotted as in
Figure 2.
doi:10.1371/journal.ppat.1002691.g003
Figure 4. Structures of NTZ analogues.
doi:10.1371/journal.ppat.1002691.g004
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loneor with NTZ or TIZ. None of the drugs, when tested between
0.5 mg/ml and 50 mg/ml(equivalent to 2.45 mM and 244.73 mM
EMB; 1.37 mM and 137.14 mM INH; 4.06 mM and 406.13 mM
PZA; 0.86 mM and 85.97 mM STM; and 0.61 mM and 60.76 mM
RMP), prevented the induction of punctate EGFP-LC3 by NTZ
or TIZ at 3 or 10 mM (Figure 8). These results predict that NTZ
would retain its ability to affect autophagy when used in
combination treatment with tuberculosis drugs.
Discussion
This study reveals new cellular roles for the antiparasitic drug
nitazoxanide and its active metabolite tizoxanide as stimulators of
autophagy and inhibitors of mTORC1 signaling, acting at least in
part through suppression of the quinone oxidoreductase NQO1.
Our work also demonstrates that these drugs inhibit Mtb
proliferation in human cells. NTZ is a noncompetitive inhibitor
of pyruvate: ferredoxin oxidoreductase (PFOR) [43], an enzyme
found in amitochondriate human parasites and most anaerobic
bacteria but that is not conserved in mammals. PFOR catalyses
the oxidative decarboxylation of pyruvate to acetyl coenzyme A
and CO2 [43,54] whereas mammals oxidize pyruvate using
pyruvate dehydrogenase, which is not inhibited by NTZ [55]. To
our knowledge, NTZ has not previously been shown to have direct
targets in human cells or to act on host cell signaling pathways.
The thiazolide RM4847 differs from TIZ in having a Br substituent
instead of a nitro group as well as methyl groups attached to the 6-
membered ring and to the 5-membered ring. RM4847 coupled to
agarose beads has been observed to bind human glutathione-S-
transferase, GSTP1 [56] and human NQO1 [49]. We did not observe
inhibition of cellular GSTP1 by NTZ (unpublished data) using the 1-
chloro-2,4-dinitrobenzene reduction GSTP1 enzymatic activity assay
[57,58]. However, NTZ inhibited cellular NQO1 enzymatic activity
in a concentration-dependent manner, strongly reducing NQO1
activity at 10 mM. Moreover, DIC, an NQO1 inhibitor, also inhibited
mTORC1 signaling. The reduction of NQO1 enzymatic activity
likely contributes to attenuation of mTORC1 signaling, since deletion
of the major mTORC1 regulator TSC1–TSC2 rendered cells
unresponsive to the effects of NTZ or DIC.NTZ and DIC were also
less potent inhibitors of mTORC1 in cells that do not express NQO1,
indicating that NQO1 is a relevant cellular target, but probably not
the only one. Thus, NTZ may stimulate autophagy and inhibit
mTORC1 signaling and intracellular Mtb proliferation at least in part
as a result of inhibiting NQO1.
NQO1 can catalyze the reduction of a broad range of reactive
substrates including quinones, quinone-imines and nitro-com-
pounds to less reactive and less toxic forms [59]. It has also been
shown to be a superoxide scavenger [60] and a ‘‘gatekeeper’’ of
the 20S proteasome [61,62]. We speculate that NQO1 may be
linked to autophagy throughp62/sequestosome-1, an adaptor
protein that binds LC3 and ubiquitin to facilitate autophagy of
polyubiquitinated proteins [63]. This speculation is based on the
observations that p62 canactivate the redox-sensing transcription
factorNrf2resulting in persistent expression of NQO1 [64] and
that knockdown of Nrf2caused a 2-fold increase in autophagy [65].
Our data linking NQO1 activity and mTORC1 signaling are in
line with studies showing that NQO1 expression is induced to
counter the toxicity of elevated levels of reactive oxygen species
(ROS) [66], and that increased oxidative stress from elevated ROS
inhibits mTORC1 signaling and induces autophagy through
activation of TSC2 [67].Pharmacological inhibition of NQO1
may increase oxidative stress to inhibit mTORC1 and activate
autophagy, thereby inhibiting intracellular Mtb proliferation.
NTZ can directly kill both replicating and nonreplicating Mtb in
vitro [68]. NTZ kills Mtb in vitro in liquid and solid media at a
minimum inhibitory concentration of ,50 mM after 7 days [68].
This occurs by an uncharacterized mechanism because PFOR is
not known to be present in Mtb [68]. This observation raises the
question of whether NTZ prevents the replication of Mtb in
human cells solely by targeting the bacteria themselves or also by
affecting a host cellular process such as autophagy. In our hands,
10 mM NTZ completely inhibited mTORC1 signaling and
strongly stimulated autophagy while this concentration directly
inhibited Mtb proliferation in liquid culture less robustly (Figure
S3). Therefore it can be argued that concentrations of NTZ that
directly kill Mtb would also necessarily affect autophagy, a host
cellular process implicated in Mtb intracellular proliferation.
Additionally, 10 mM NTZ inhibited the intracellular replication
of Mtb in THP-1 cells more strongly than it inhibited Mtb directly.
The interpretation of this latter result is complicated by the
observation that the PI exclusion assay, but not the MTT or
Hoechst assays, showed 10 mM NTZ to be significantly toxic to
differentiated THP-1 cells at longer exposure times. More
importantly, all assays showed NTZ was not toxic to PBMC at
the highest concentration and exposure time tested (30 mM, 72 h),
consistent with its very safe toxicity profile in humans. Indeed, a
peak plasma concentration of 37 mM TIZ was observed after a
standard single oral dose of 500 mg NTZ while1 g administered
twice daily for one week resulted in peak plasma concentrations
Table 1. Effect of Nitazoxanide analogs (10 mM) on autophagosome induction, EGFP-LC3 and mTORC1 inhibition.
Analogue Autophagosome formation EGFP-LC3 processing mTORC1 inhibition
DMSO 222
NTZ +++ +++ +++
TIZ +++ +++ +++
1 222
2 222
3 222
4 ++ + +
5 +++ +++ +++
6 ++ + +
7–16 222
doi:10.1371/journal.ppat.1002691.t001
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effects [30]. Therefore, the toxicity of NTZ towards the
differentiated THP-1 cell line in culture does not appear to reflect
the in vivo situation. NTZ also inhibited the intracellular
proliferation of Mtb in PBMC. Significant inhibition required a
concentration of 10–30 mM (Figure 6), the range reflecting
different sensitivities of PBMC from different donors.
In our experiments, NTZ and rapamycin both efficiently
inhibited mTORC1 but NTZ reduced intracellular Mtb prolifer-
ation while rapamycin did not. This result is in apparent contrast
with a previous report that rapamycin reduced Mtb replication in
RAW 264.7 cells [19]. Different experimental conditions may
explain this discrepancy, including the use of a much higher
rapamycin concentration of 50 mM. Here, we used 30 nM, which
was sufficient to completely inhibit the phosphorylation of S6K by
mTORC1 in THP-1 cells. A more recent study reported ,50%
reduction in Mtb colony-forming units after 4 h treatment of
infected THP-1 cells with 27 mM rapamycin [69].
Anti-tuberculosis drugs are limited in number and efficacy and
prone to many side effects and are often inactive against
nonreplicating (dormant) Mtb. Furthermore, multi drug-resistant
strains are resistant to the first-line drugs rifampicin and isoniazid
and extensively drug-resistant strains are also resistant to any
fluoroquinolone and any of the second-line injectable drugs, and
give very high mortality rates [2,70]. Even non-resistant strains of
Mtb can require up to nine months of therapy with a combination
of at least three antibiotics to reduce development of resistance
[71,72]. Therefore new drugs with improved efficacy, shorter
treatment time and lower cost are urgently needed.
NTZ is a safe, effective, orally bioavailable and inexpensive drug
already approved for human use. It has shown broad-spectrum
activity against anaerobic intestinal helminths and protozoans as
well as some bacteria, including Clostridium difficile [73–79] and is
approved for the treatment of enteritis caused by Cryptosporidium
parvum and Giardia intestinalis [29]. The length of NTZ treatment is
typically 3–14 days, but it has been used for up to 4 years in AIDS-
related cryptosporidiosis patients without significant adverse effects
[77,80] and resistance to NTZ has not been reported. NTZ
inhibited mTORC1, modulated autophagy, inhibited NQO1 and
inhibited Mtb proliferation in PBMC at concentrations well within
tolerated plasma concentrations. The autophagy-stimulating effect
of NTZ was not impaired in the presence of the anti-tuberculosis
drugs ethambutol, isoniazid, pyrazinamide, streptomycin, or
rifampicin. Drugs such as NTZ that both directly inhibit the
proliferation of pathogenic microorganism and stimulate host
cellular defense mechanisms such as autophagy may provide new
opportunities to combat intracellular pathogens like Mtb.
Materials and Methods
Ethics statement
Peripheral blood was collected from normal human subjects, in
accordance with the ethics approval guidelines of the University of
British Columbia Research Ethics Board and Tri-Council Policy
Statement for Ethical Conduct for Research Involving Humans,
for secondary use of anonymous human blood. Written informed
consent was obtained from all study participants.
Reagents
Cell culture reagents were purchased from Invitrogen, unless
stated otherwise. General laboratory chemicals were purchased
from Sigma-Aldrich, Fisher Scientific and BDH Inc. Nitazoxanide
(N490100) and tizoxanide(T450100) were purchased from Toronto
Research Chemicals Inc, rapamycin (553210) from Calbiochem,
and Hoechst 33342 (H3570) from Invitrogen. Dicoumarol (Sigma
M1390) was prepared fresh in DMSO before each experiment.
Anti-phospho Thr389 S6K (#9205), anti- phospho Ser473 Akt
(#9271), anti-Akt (#9272), and anti-NQO1 (#3187) antibodies
were from Cell Signaling Technology. Anti-S6K C-18 (#230)
antibody was purchased from Santa Cruz Biotechnology, and anti-
GFP antibody (#1814460) was from Roche. Antibody to endog-
enous LC3 was purchased from Nanotools (0260-100). The M.
tuberculosis H37Rv strain carrying pMV361-c1-lucplasmid was used
for macrophage infection studies. pMV361-c1-luc carries a 1.65 kb
fragment of the firefly luciferase gene under constitutive expression
of a mycobacterial HSP60 promoter [81].
Cell culture procedures
MCF-7 cells stably transfected with pEGFP-LC3 have been
described previously [28]. These cells were maintained in RPMI-
1640 medium (Invitrogen 72400) supplemented with 400 mg/mL
G418 (Promega #V7982) and 10% (v/v) fetal bovine serum (FBS)
with 2 g/L sodium bicarbonate and 1 mM HEPES. THP-1 cells
were maintained in RPMI-1640 supplemented with 10% FBS and
1% glutamine.TSC2
2/2/p53
2/2 and TSC2
+/+/p53
2/2 mouse
embryo fibroblasts (MEF) were a generous gift of Dr. David
Kwiatkowski [82]. MEF and HEK 293T cells were maintained in
high glucose Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% FBS.
Automated assay for autophagosome induction
MCF-7 cells stably expressing EGFP-LC3 were seeded at
20,000 cells/well in PerkinElmer View 96-well plates. Eighteen
hours after seeding, chemicals were added to each well and plates
were incubated at 37uC for the indicated times. The medium was
removed and cells were fixed with 3% (v/v) paraformaldehyde
containing 500 ng/mL Hoechst 33342 for 15 min at room
temperature. Fixed cells were washed once with PBS containing
1 mM MgCl2 and 0.1 mM CaCl2 and stored in the same medium
at 4uC overnight. Plates were scanned using a Cellomics
TMAr-
rayscan VTI automated fluorescence imager. Cells were photo-
graphed and quantified using the compartment analysis algorithm
as previously described [28].
Cell lysis and protein quantification
Cells were harvested in 20 mM Tris-HCl pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton X-100,
Figure 5. Effect of NTZ on Mtb proliferation and survival of THP-1 cells. (A) Differentiated THP-1 cells infected with Mtb H37Rv bearing a
luciferase-reporting plasmid were treated with various concentrations of NTZ or TIZ for the indicated times. Intracellular Mtb was measured as
luciferase activity at 24, 48 and 72 h. (B) Infected THP-1 cells were treated as in (A) but after 24 h treatment the drugs were removed and cells were
incubated with medium without drug. Luciferase activity was measured at 24 h, 48 h (24 h post-wash) and 72 h (48 h post-wash). (C) Differentiated
THP-1 cells were exposed to various concentrations of NTZ, TIZ or rapamycin for 4 h. Endogenous LC3 processing (using LC3 antibodies) and
mTORC1 activity were determined by immunoblotting as in Figure 2.Viability of THP-1 cells treated with drugs for the indicated times was measured
with the MTT assay (D) or by propidium iodide (PI) staining (E, F). PI levels were measured quantitatively by automated microscopy, and viable cells
was calculated as the percentage of PI-negative cells. (F) After drug removal at 24 h, THP-1 cell survival was measured by PI at 48 h (24 h post-wash)
and 72 h (48 h post-wash).
doi:10.1371/journal.ppat.1002691.g005
NTZ Induces Autophagy, Inhibits Mtb Proliferation
PLoS Pathogens | www.plospathogens.org 9 May 2012 | Volume 8 | Issue 5 | e1002691NTZ Induces Autophagy, Inhibits Mtb Proliferation
PLoS Pathogens | www.plospathogens.org 10 May 2012 | Volume 8 | Issue 5 | e10026912.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate sup-
plemented with fresh 1 mM Na3VO4, 1 mM dithiothreitol, and
16 complete protease inhibitor cocktail (Roche, #1169748001).
Supernatants were collected after centrifugation at 18,0006g for
15 min at 4uC and quantified using the BCA protein assay kit
(Pierce #23227).
SDS-PAGE and immunoblotting
Electrophoresis and immunoblotting conditions for EGFP-LC3
processing, S6K and AKT in MCF-7, THP-1 and HEK 293T
cells were exactly as previously described [28]. MEF were seeded
in 6-well plates at 400,000 cells/well (TSC2
+/+) or 200,000 cells/
well (TSC2
+/+) in normal DMEM medium, cultured overnight
and treated similarly.NQO1 levels were assessed by resolving
protein samples on a 10% acrylamide gel and subjected to
electroblotting onto nitrocellulose, then blocked with 5% (w/v) fat-
free milk and incubated with NQO1 antisera. For immunoblotting
of endogenous LC3, proteins were transferred onto polyvinylidene
fluoride membrane with membrane with 0.2 mm pores, which
were then fixed with 0.2% glutaraldehyde in PBS with 0.02%
Tween-20 for 20 min at room temperature, prior to blocking with
5% fat-free milk.
Synthesis of nitazoxanide analogues
Analogues 1, 10, 11 were prepared by coupling between benzoyl
chloride and heteroaromatic primary amines. Analogues 2, 12, 13
were prepared by coupling between 2-ethoxybenzoyl chloride and
heteroaromatic primary amines. Analogues 4, 5, 6, 8, 9, 14, 15, 16
were prepared by coupling between salicyloyl chloride esters and
heteroaromatic primary amines. Analog 3 was prepared by
coupling between 2-(methoxycarbonyl)benzoyl chloride and 2-
amino-5-nitrothiazole. Analogue 7 was prepared by methylation of
nitazoxanide using the methylating agent iodomethane and
K2CO3. Full details are given in the Supporting Information.
THP-1 differentiation, Mtb co-infection and luciferase
assay
THP-1 cells were differentiated for 24 h with 40 mM PMA in
RPMI-1640 medium supplemented with 10% FBS and 1%
glutamine. For macrophage co-infection, cell suspensions were
differentiated in 96-well plates and incubated at 37uC overnight.
The cells were washed 3 times with 100 ml RPMI medium before
infection. Mtb cultures, grown in Middlebrook 7H9 supplemented
with oleic acid-albumin-dextrose-catalase (OADC) and 0.05%
Tween 80, were washed with 7H9 medium and the bacteria were
opsonized by resuspension in RPMI-1640 medium containing
10% human serum for 30 min at 37uC. Donor-specific serum was
used for the infection of PBMC. The opsonized bacteria were
resuspended in RPMI-1640 and added to differentiated THP-1
cells or PBMC at a multiplicity of infection (MOI) of 1 or 10 for
3.5 h at 37uCi n5 %C O 2. The cells were washed gently 3 times
with RPMI-1640 to remove non-internalized bacteria and then
incubated in 100 ml of RPMI-1640 containing 1% glutamate and
10% FBS. After 24 h, the medium was aspirated and replaced
with medium containing test compounds. After 24, 48 or 72 h, the
medium was aspirated and 100 ml Bright-Glo reagent (Promega
TM052) was added. After 10 min incubation, luciferase activity
was measured with aTropix TR7171 luminometer (Applied
Biosystems).
Isolation of human PBMC
Peripheral blood was collected from normal human subjects, in
accordance with the ethics approval guidelines as stated above.
Blood was collected in BD Vacutainer Plus plastic plasma tubes
coated with sodium heparin (158 USP units) (BD Diagnostics
#367874). Blood from a single donor was diluted 1:1 with PBS,
layered over Ficoll-Paque PLUS (Stemcell Technologies
#07957), and centrifuged at 900 g for 30 min according to
manufacturer’s instructions. White blood cells were isolated from
buffy coats after centrifugation, and their viability was assessed by
Trypan blue to be .98%. 5610
6white blood cells were plated
directly in 96-well assay plates in RPMI-1640 supplemented with
5% donor-specific human serum. Human serum was prepared
from the plasma portion of the Ficoll gradient, heat-inactivated at
55uC for 30 min, centrifuged at 3,0006g for 20 min and filter
sterilized before use. PBMC were allowed to adhere to plates for
20–24 h, after which cells were washed 2–3 times with
supplemented RPMI to remove non-monocytic cells. Adherent
cells were subsequently infected or treated with drugs as
described above.
Viability assays
The viability of PBMC or differentiated THP-1 cells infected
with M. tuberculosis in 96-well plates was measured at 24, 48 and
72 h using the (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl-tetrazo-
lium bromide (MTT) assay (M2128, Sigma) as described [83]. For
propidium iodide (PI) and nuclear staining assays, 100 ml of pre-
warmed RPMI-1640 containing propidium iodide (Sigma-Aldrich
P-4170) and Hoechst 33342was added directly to wells at
indicated timepoints, to final concentrations of0.25 mg/ml and
0.5 mg/ml, respectively. Plates were incubated at 37ufor 30 min,
and scanned using the CellomicsArrayscan VTI automated
fluorescence imager. The cells were imaged with a 206objective
with the Hoechst and TRITC (Ch2, red) channel, and data was
collected from at least 800 cells per well. The target activation
algorithm was applied to obtain a nuclear mask in the Hoechst
channel and corresponding cytoplasmic mask applied in the
TRITC channel to quantitate cell number and PI positive cells,
respectively. The untreated wells were identified as reference wells
during the scan. PI-positive cells show up as bright fluorescent
objects in Ch2, with a higher intensity than live cells. The data
output ‘‘% responder_AvgIntenCh2’’ is the percentage of cells
with average intensity in cytoplasmic mask Ch2which had higher
average intensity than that of untreated cells. Cell viability was
calculated as the proportion of cells that were propidium iodide-
negative.
NQO1 enzymatic activity assay
NQO1 activity was measured using a modified version of the
Prochaska microtiter plate bioassay, which measures enzymatic
activity based on the menadione-mediated reduction of MTT
[50,51].0.25 mg/ml of purified NQO1 enzyme (human DT
Diaphorase, Sigma D1315) in dH2O, or fresh lysates from
MCF-7 cells were used in each reaction in a 96-well plate format.
Figure 6. Effects of NTZ on Mtb proliferation and viability of PBMC. Peripheral blood mononuclear cells isolated from healthy human
subjects and infected with Mtb H37Rv bearing a luciferase-reporting plasmid were treated with various concentrations of NTZ for the indicated times.
Intracellular Mtb was measured as luciferase activity. Data presented are: subject 1withMOI 10 (A), subject 2with MOI 1 (B) and subject 2 with MOI 10
(C). Viability normalized to DMSO-treated controls was measured at 48 and 72 h, with PBMC from subject 2 using the MTT assay (D) or by PI staining
(E).(F) Viability, normalized to DMSO treated controls, was measured with PBMC from subject 3 at 72 h.
doi:10.1371/journal.ppat.1002691.g006
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Prochaska microtiter plate bioassay, in which 0.25 mg/ml pure NQO1 enzyme was treated with different concentrations of NTZ, dicoumarol (DIC), and
rapamycin (RAPA) for 1 h. (B) MCF-7 cell lysates were treated with various concentrations of NTZ for 1 h, and relative activity of NQO1 was
determined by the Prochaska bioassay. (C) MCF-7 cells or (D) TSC2
+/+ and TSC2
2/2MEFs were treated with NTZ, DIC, and rapamycin for 4 h and
subjected to immunoblotting for total and phosophorylated S6K as previously described.(E) Total NQO1 or (F) total and phosphorylated S6K was
assessed by immunoblotting in MCF-7 or HEK 293T cells treated with indicated concentrations of drugs for 8 h. Lines in (F) were used to indicate
juxtaposition of noncontinguous lanes from the same gel and image exposure.
doi:10.1371/journal.ppat.1002691.g007
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washed and resuspended in cold PBS. 9610
6 cells were collected
by scraping, and lysed in cold 0.56PBS by passing 15 times
through a 1 mL syringe with a 26 gauge K in needle. Lysis was
performed on ice. The lysates were diluted in cold 0.56PBS to
seed an equivalent of 10,000 cells per well. Wells were then
treated with the indicated concentrations of drugs diluted in
16PBS, at room temperature. After 1 h incubation at 37uC,
200 mL of fresh reaction mixture (25 mM Tris HCl pH 7.4,
0.01% Tween-20, 5 mM FAD, 1 mM G6P, 30 mM NADP, 60 U
G6PD, 0.67 mg/mlbovine serum albumin, 0.3 mg/mlMTT,
and 25 mM menadione) was added to each well at room
temperature. Parallel reactions using reaction mixture without
menadione were used as controls, and wells containing reaction
mixture only were used as nonenzymatic blanks. After 5 min
incubation at room temperature, the reaction was arrested with
0 . 3m M d i c o u m a r o l i n 0 . 5 % D M S O a n d 5m M p o t a s s i u m
phosphate pH 7.4. Plates were scanned at 595 nm at 5 min
intervals with a spectrophotometer.
Accession numbers (UniProtKB/SwissProt)
LC3 (Q9H492); mTOR (P42345); PKB/Akt (P31749); S6K
(P23443); TSC2 (Q7TT21); NQO1 (P15559); glutathione-S-
transferase P1 (P09211); p62/sequestosome 1 (Q13501); Nrf2
(Q16236).
Supporting Information
Figure S1 EGFP-LC3 localization in cells treated with
NTZ or TIZ. MCF-7 cells stably expressing EGFP-LC3 were
incubated for 3 h or 24 h with different concentrations of NTZ,
TIZ or DMSO. EGFP-LC3 is depicted in green and DNA in blue.
Scale bar, 10 mm.
(TIF)
Figure S2 Additional nitazoxanide analogues. These
analogues were tested for induction of autophagosome accumu-
lation, induction of EGFP-LC3 processing and mTORC1
inhibition and found to be inactive in all three assays.
(TIF)
Figure 8. Effect of NTZ and TIZ on autophagosome formation in the presence of tuberculosis drugs. MCF-7 cells expressing EGFP-LC3
were exposed to 3 mMo r1 0mM NTZ (A) or TIZ (B), without or with 5 mg/ml ethambutol (EMB), pyrazinamide (PZA), isoniazid (INH), streptomycin
(STM) or rifampicin(RMP). Representative images of treated cells are shown in (C). Scale bar, 10 mm.
doi:10.1371/journal.ppat.1002691.g008
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PLoS Pathogens | www.plospathogens.org 13 May 2012 | Volume 8 | Issue 5 | e1002691Figure S3 Effect of NTZ on Mtb. Mtb cultures seeded in
liquid medium at OD of 0.1 were treated with drugs at indicated
concentrations, and growth of the same culture was measured after
48, and 72 h by (A) OD, or (B) luciferase activity.
(TIF)
Figure S4 Effect of rapamycin on Mtb. Differentiated
THP-1 cells infected with Mtb H37Rv bearing a luciferase-
reporting plasmid were treated with various concentrations
rapamycin for 24, 48, and 72 h. Intracellular Mtb was measured
as luciferase activity.
(TIF)
Supporting Information Supplemental materials and
methods.
(DOCX)
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